Effect of pegylated interferon and ribavirin therapy on the QOL in the treatment of chronic hepatitis C - TOPIQS study

Tokai University School of Medicine, Department of Internal Medicine, Division of Gastroenterology0 个研究点目标入组 60 人开始时间: 2010年8月10日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Patients who were previously treated with pegylated interferon and ribavirin therapy. 2. Patients who are pregnant or lactating. 3. Patients who cannot use birth control until 6 months pass after the end of treatment. 4. Patients who have hypersensitivity to interferons or ribavirin. 5. Patients who have uncontrolled heart diseases. 6. Patients with abnormal hemoglobin diseases. 7. Patients with chronic renal failure. 8. Patients with severe depression. 9. Patients with severe liver diseases. 10. Patients with autoimmune disorders. 11. Patients receiving other antiviral drugs, immunomodulating drugs, or Sho-Sai-Ko-To. 12. Patients who have hypersensitivity to aspirin or NSAID. 13. Patients who have peptic ulcers. 14. Patients who have asthma induced by aspirin or NSAID. 15. Patients who received antiviral therapy within 6 months. 16. Patients who have a history of interstitial pneumonia.

发起方

Tokai University School of Medicine, Department of Internal Medicine, Division of Gastroenterology